Corcept Therapeutics price target raised by $1 at Canaccord, here’s why

Canaccord raised the firm’s price target on Corcept Therapeutics to $38 from $37 and keeps a Buy rating on the shares after having had the opportunity to travel with the CFO through the Midwest. The multi-city trip “resulted in strong investor interest with a heavy slant on Korlym’s growth, relacorilant’s commercial opportunity in Cushing’s and the potential outcome of the Teva litigation,” reports the analyst, who increased the insurance coverage rate to reflect what is currently seen with Korlym as well as the patient compliance rate for relacorilant.